{"id":337932,"date":"2025-08-19T13:12:04","date_gmt":"2025-08-19T13:12:04","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-merck\/"},"modified":"2025-08-19T13:12:04","modified_gmt":"2025-08-19T13:12:04","slug":"how-to-buy-merck","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/","title":{"rendered":"Merck &#038; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Merck &#038; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-337932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck & Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m","h1_source":{"label":"H1","type":"text","formatted_value":"Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck & Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m"},"description":"Merck & Co., Inc. (MRK) hisseleri nas\u0131l al\u0131n\u0131r ve Merck & Co., Inc. (MRK) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r, mevcut fiyat, trendler ve gelece\u011fe y\u00f6nelik beklentilerle ilgili kapsaml\u0131 analizimizle \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Merck & Co., Inc. (MRK) hisseleri nas\u0131l al\u0131n\u0131r ve Merck & Co., Inc. (MRK) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131l\u0131r, mevcut fiyat, trendler ve gelece\u011fe y\u00f6nelik beklentilerle ilgili kapsaml\u0131 analizimizle \u00f6\u011frenin."},"intro":"Portf\u00f6y\u00fcn\u00fcze bir ila\u00e7 devi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Merck & Co., Inc. (sembol: MRK), bug\u00fcn mevcut en istikrarl\u0131 ve yenilik\u00e7i sa\u011fl\u0131k yat\u0131r\u0131mlar\u0131ndan biridir. 350 y\u0131ll\u0131k miras\u0131 ve b\u00fcy\u00fcmeyi tetikleyen Keytruda gibi blockbuster ila\u00e7lar\u0131yla bu \u015firket hem savunma \u00f6zellikleri hem de heyecan verici y\u00fckseli\u015f potansiyeli sunar. Bu yat\u0131r\u0131m\u0131 sizin i\u00e7in nas\u0131l i\u015fe yarar hale getirece\u011finizi her y\u00f6n\u00fcyle a\u00e7\u0131klayaca\u011f\u0131z.","intro_source":{"label":"Intro","type":"text","formatted_value":"Portf\u00f6y\u00fcn\u00fcze bir ila\u00e7 devi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Merck & Co., Inc. (sembol: MRK), bug\u00fcn mevcut en istikrarl\u0131 ve yenilik\u00e7i sa\u011fl\u0131k yat\u0131r\u0131mlar\u0131ndan biridir. 350 y\u0131ll\u0131k miras\u0131 ve b\u00fcy\u00fcmeyi tetikleyen Keytruda gibi blockbuster ila\u00e7lar\u0131yla bu \u015firket hem savunma \u00f6zellikleri hem de heyecan verici y\u00fckseli\u015f potansiyeli sunar. Bu yat\u0131r\u0131m\u0131 sizin i\u00e7in nas\u0131l i\u015fe yarar hale getirece\u011finizi her y\u00f6n\u00fcyle a\u00e7\u0131klayaca\u011f\u0131z."},"body_html":"<h2>\ud83d\udcc8 Merck Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla Merck & Co., Inc. (MRK) NYSE'de <strong>84,22 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>30 Ekim 2025<\/strong> kesinlikle kritik. Merck'in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu ve tarihsel olarak bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine neden oluyor.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 MRK Hissesini Nas\u0131l Hareket Ettirir?<\/h3> <p>Son desenlere g\u00f6re, Merck'in kazan\u00e7 a\u00e7\u0131klamalar\u0131 genellikle 48 saat i\u00e7inde %3-8 aras\u0131nda fiyat dalgalanmalar\u0131na yol a\u00e7\u0131yor. \u015eirketin 29 Temmuz 2025'teki son raporu, d\u00fcnya \u00e7ap\u0131nda 15,8 milyar $ sat\u0131\u015f ve tahminleri %3,26 a\u015fan 2,13 $ non-GAAP EPS ile etkileyici sonu\u00e7lar g\u00f6sterdi (<a href=\"https:\/\/www.merck.com\/news\/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results\/\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>).<\/p> <p>Tarihsel veriler, pozitif kazan\u00e7 s\u00fcrprizlerinin genellikle takip eden hafta i\u00e7inde hisseyi %4-6 art\u0131rd\u0131\u011f\u0131n\u0131, tahminlerin alt\u0131nda kal\u0131nd\u0131\u011f\u0131nda ise ge\u00e7ici %3-5 d\u00fc\u015f\u00fc\u015fler ya\u015fand\u0131\u011f\u0131n\u0131 ve ard\u0131ndan toparland\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Merck'in tahminleri a\u015fma ge\u00e7mi\u015fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, Ekim raporu g\u00fczel bir kataliz\u00f6r olabilir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h2> <p>Merck hisseleri son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi, hem dayan\u0131kl\u0131l\u0131k hem de volatilite g\u00f6sterdi:<\/p> <p><strong>Mart 2025<\/strong>: 97,37 $ (7 Mart'ta alt\u0131 ayl\u0131k zirve)<br\/> <strong>Nisan 2025<\/strong>: 85-90 aral\u0131\u011f\u0131 (konsolidasyon d\u00f6nemi)<br\/> <strong>May\u0131s 2025<\/strong>: 73,31 $ (15 May\u0131s'ta alt\u0131 ayl\u0131k dip - tarife endi\u015feleri)<br\/> <strong>Haziran 2025<\/strong>: 79,16 $ (toparlanma ba\u015flad\u0131)<br\/> <strong>Temmuz 2025<\/strong>: 78,12 $ (yaz d\u00f6nemi istikrar\u0131)<br\/> <strong>A\u011fustos 2025<\/strong>: 84,21 $ (mevcut toparlanma ivmesi)<\/p> <p>Bu, May\u0131s diplerinden itibaren <strong>%14,87'lik bir toparlanma<\/strong> anlam\u0131na geliyor ve hissenin gerilemelerden toparlanma yetene\u011fini g\u00f6steriyor (<a href=\"https:\/\/www.barchart.com\/stocks\/quotes\/mrk\/performance\">Performans Verileri<\/a>). Zirve ve dipler aras\u0131ndaki yakla\u015f\u0131k 24 $'l\u0131k i\u015flem aral\u0131\u011f\u0131, ila\u00e7 hisselerinde zamanlaman\u0131n neden \u00f6nemli oldu\u011funu a\u00e7\u0131kl\u0131yor.<\/p> <h3>Volatilitenin Sebebi Nedir?<\/h3> <ul> <li><strong>May\u0131s'taki tarife endi\u015feleri<\/strong> keskin d\u00fc\u015f\u00fc\u015fe neden oldu<\/li> <li><strong>Keytruda patent u\u00e7urumu<\/strong> kayg\u0131s\u0131 sat\u0131\u015f bask\u0131s\u0131 yaratt\u0131<\/li> <li><strong>Temmuz'daki g\u00fc\u00e7l\u00fc 2. \u00e7eyrek kazan\u00e7lar\u0131<\/strong> destek sa\u011flad\u0131<\/li> <li><strong>2025 boyunca yeni ila\u00e7 onaylar\u0131<\/strong> g\u00fcven olu\u015fturdu<\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 Beklentileri<\/h2> <h3>2025 Y\u0131l Sonu: 85-95 $ Aral\u0131\u011f\u0131 \u2192 AL<\/h3> <p>Analistler, Merck'in 2025'i 85-95 $ aras\u0131nda tamamlayabilece\u011fini \u00f6ng\u00f6r\u00fcyor; bu da mevcut seviyelerden %1-13 aras\u0131nda potansiyel y\u00fckseli\u015f anlam\u0131na geliyor. 77,08 $'l\u0131k muhafazakar tahmin, son momentum g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda fazla k\u00f6t\u00fcmser g\u00f6r\u00fcn\u00fcyor (<a href=\"https:\/\/tradersunion.com\/currencies\/forecast\/mrk-usd\/\">2025 Tahmini<\/a>).<\/p> <h3>2026 Projeksiyonu: 89-92 $<\/h3> <p>Y\u0131l ortas\u0131 hedefleri yakla\u015f\u0131k 89,63 $ ve y\u0131l sonu 92,35 $ seviyeleri, \u00fcr\u00fcn hatt\u0131 geli\u015fmeleri ve pazar geni\u015flemesine dayanarak makul g\u00f6r\u00fcn\u00fcyor.<\/p> <h3>2028 Beklentisi: 101-104 $<\/h3> <p>2028'e kadar Merck'in \u00e7e\u015fitlendirme \u00e7abalar\u0131 meyvesini vermeli ve hisse senedi y\u0131llard\u0131r ilk kez 100 $'\u0131n \u00fczerine \u00e7\u0131kmal\u0131.<\/p> <h3>2030 Vizyonu: 117-187 $<\/h3> <p>Uzun vadeli tahminler, patent biti\u015fleri ve yeni ila\u00e7 ba\u015far\u0131s\u0131na ili\u015fkin belirsizli\u011fi yans\u0131tarak muhafazakar 117 $ ile iyimser 187 $ aras\u0131nda geni\u015f bir aral\u0131kta de\u011fi\u015fiyor (<a href=\"https:\/\/stockscan.io\/stocks\/MRK\/forecast\">Uzun Vadeli Projeksiyonlar<\/a>).<\/p> <p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut de\u011ferleme, 9 kat ileriye d\u00f6n\u00fck F\/K oran\u0131yla tarihsel ortalamalara g\u00f6re \u00f6nemli bir indirim sunuyor.<\/p> <h2>\u26a0\ufe0f \u00d6nemli Riskler ve Pozitif \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Patent U\u00e7urumu Kayg\u0131s\u0131<\/strong>: Keytruda'n\u0131n yakla\u015fan patent s\u00fcresi belirsizlik yarat\u0131yor, \u00f6nlemlere ra\u011fmen (<a href=\"https:\/\/monexa.ai\/blog\/merck-s-strategy-navigating-keytruda-cliff-with-pi-MRK-2025-06-05\">Patent Stratejisi<\/a>)<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA onay s\u00fcre\u00e7leri zorlu ve \u00f6ng\u00f6r\u00fclemez olmaya devam ediyor<\/li> <li><strong>Tarife Maruziyeti<\/strong>: 2025 i\u00e7in beklenen 200 milyon $ tarife maliyeti k\u00e2r marjlar\u0131n\u0131 etkileyebilir<\/li> <li><strong>Rekabetin Artmas\u0131<\/strong>: Rakipler benzer onkoloji tedavileri geli\u015ftiriyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>\u00dcr\u00fcn Hatt\u0131 G\u00fcc\u00fc<\/strong>: Geli\u015ftirilmekte olan 20 potansiyel blockbuster ila\u00e7, 50 milyar $'dan fazla f\u0131rsat sunuyor<\/li> <li><strong>Son FDA Ba\u015far\u0131lar\u0131<\/strong>: KEYTRUDA geni\u015flemesi, ENFLONSIA onay\u0131, WELIREG pediatrik endikasyonu<\/li> <li><strong>Stratejik Sat\u0131n Alma<\/strong>: Solunum portf\u00f6y\u00fcne Ohtuvayre ekleyen 10 milyar $'l\u0131k Verona Pharma anla\u015fmas\u0131<\/li> <li><strong>WINREVAIR Ba\u015far\u0131s\u0131<\/strong>: 2. \u00e7eyrekte 336 milyon $ sat\u0131\u015f, toplamda 1 milyar $'\u0131 a\u015fan gelir<\/li> <li><strong>Temett\u00fc G\u00fcc\u00fc<\/strong>: %3,8 getiri ve s\u00fcrd\u00fcr\u00fclebilir %49 \u00f6deme oran\u0131<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Haftal\u0131k veya ayl\u0131k al\u0131mlarla dolar maliyeti ortalamas\u0131 yap\u0131n<\/li> <li><strong>Kazan\u00e7 uyar\u0131lar\u0131 kurun<\/strong> - Potansiyel giri\u015f noktalar\u0131 i\u00e7in 30 Ekim civar\u0131n\u0131 takip edin<\/li> <li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong> - \u0130la\u00e7 hisseleri, \u00fcr\u00fcn hatt\u0131n\u0131n olgunla\u015fmas\u0131 i\u00e7in sab\u0131r gerektirir<\/li> <li><strong>Do\u011fru \u00e7e\u015fitlendirin<\/strong> - MRK'yi toplam portf\u00f6y\u00fcn %5-10'u ile s\u0131n\u0131rlay\u0131n<\/li> <\/ol> <p>Espiri: \"MRK ticareti yapmak, klinik deneme sonu\u00e7lar\u0131n\u0131 beklemek gibidir - bazen \u00e7\u0131\u011f\u0131r a\u00e7an tedavi onay\u0131 al\u0131rs\u0131n\u0131z, bazen yan etkilerle kar\u015f\u0131la\u015f\u0131rs\u0131n\u0131z. Her hal\u00fckarda, g\u00fc\u00e7l\u00fc mide ilac\u0131na ihtiyac\u0131n\u0131z olacak!\"<\/p> <h2>\u2705 Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NYSE eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"MRK\" sembol\u00fcn\u00fc aray\u0131n<\/td><td>Sadece \"Merck\" de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapman\u0131z\u0131 engeller<\/td><\/tr> <tr><td>5<\/td><td>G\u00f6zden ge\u00e7irin ve onaylay\u0131n<\/td><td>Son onaydan \u00f6nce komisyon oranlar\u0131n\u0131 kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, borsaya giri\u015fin daha az korkutucu olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in ideal<\/li> <li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> - Herhangi bir resmi kimlik y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Kripto, e-c\u00fczdan ve geleneksel bankac\u0131l\u0131k ile esneklik<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> - MRK gibi pahal\u0131 hisselerin k\u00fc\u00e7\u00fck par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, sa\u011fl\u0131k sekt\u00f6r\u00fc b\u00fcy\u00fcmesine maruz kalmak isteyen yeni ba\u015flayanlar i\u00e7in karma\u015f\u0131k ila\u00e7 hisselerini \u00e7ok daha kolay hale getiriyor.<\/p> <h2>\ud83c\udf0d 2025'te Merck: Sa\u011fl\u0131kta Yenilik Motoru<\/h2> <p>Merck, y\u0131ll\u0131k yakla\u015f\u0131k 61 milyar $ gelir ve 330 milyar $'\u0131n \u00fczerinde piyasa de\u011feri ile bir ila\u00e7 devi olarak duruyor (<a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/mrk-history-mission-ownership\">\u015eirket Metrikleri<\/a>). \u00dcnl\u00fc kanser ila\u00e7lar\u0131n\u0131n \u00f6tesinde, a\u015f\u0131 geli\u015ftirme, hayvan sa\u011fl\u0131\u011f\u0131 ve \u00e7e\u015fitli terap\u00f6tik alanlarda lider konumda.<\/p> <p>\u015eirketin \u00fcr\u00fcn hatt\u0131 2021'den bu yana neredeyse \u00fc\u00e7 kat\u0131na \u00e7\u0131kt\u0131; 20 potansiyel blockbuster ila\u00e7, gelecekte 50 milyar $'dan fazla gelir potansiyeli sunuyor (<a href=\"https:\/\/fortune.com\/well\/2025\/02\/04\/merck-touts-new-blockbuster-drugs-50-billion-potential\/\">\u00dcr\u00fcn Hatt\u0131 De\u011feri<\/a>). Son ba\u015far\u0131lar aras\u0131nda WINREVAIR'in 2. \u00e7eyrekte 336 milyon $ sat\u0131\u015f yapmas\u0131 ve solunum ilac\u0131 Ohtuvayre'yi ekleyen 10 milyar $'l\u0131k Verona Pharma sat\u0131n almas\u0131 yer al\u0131yor.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: Merck, 1898'de ABD'de ticari olarak kullan\u0131lan ilk \u00e7i\u00e7ek hastal\u0131\u011f\u0131 a\u015f\u0131s\u0131n\u0131 satt\u0131 ve bug\u00fcn hala bebeklerde RSV \u00f6nlemi i\u00e7in FDA onay\u0131 alan ENFLONSIA ile a\u015f\u0131 tarihinde yer almaya devam ediyor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Merck Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla Merck &#038; Co., Inc. (MRK) NYSE&#8217;de <strong>84,22 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>30 Ekim 2025<\/strong> kesinlikle kritik. Merck&#8217;in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu ve tarihsel olarak bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine neden oluyor.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 MRK Hissesini Nas\u0131l Hareket Ettirir?<\/h3>\n<p>Son desenlere g\u00f6re, Merck&#8217;in kazan\u00e7 a\u00e7\u0131klamalar\u0131 genellikle 48 saat i\u00e7inde %3-8 aras\u0131nda fiyat dalgalanmalar\u0131na yol a\u00e7\u0131yor. \u015eirketin 29 Temmuz 2025&#8217;teki son raporu, d\u00fcnya \u00e7ap\u0131nda 15,8 milyar $ sat\u0131\u015f ve tahminleri %3,26 a\u015fan 2,13 $ non-GAAP EPS ile etkileyici sonu\u00e7lar g\u00f6sterdi (<a href=\"https:\/\/www.merck.com\/news\/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results\/\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>).<\/p>\n<p>Tarihsel veriler, pozitif kazan\u00e7 s\u00fcrprizlerinin genellikle takip eden hafta i\u00e7inde hisseyi %4-6 art\u0131rd\u0131\u011f\u0131n\u0131, tahminlerin alt\u0131nda kal\u0131nd\u0131\u011f\u0131nda ise ge\u00e7ici %3-5 d\u00fc\u015f\u00fc\u015fler ya\u015fand\u0131\u011f\u0131n\u0131 ve ard\u0131ndan toparland\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Merck&#8217;in tahminleri a\u015fma ge\u00e7mi\u015fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, Ekim raporu g\u00fczel bir kataliz\u00f6r olabilir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h2>\n<p>Merck hisseleri son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi, hem dayan\u0131kl\u0131l\u0131k hem de volatilite g\u00f6sterdi:<\/p>\n<p><strong>Mart 2025<\/strong>: 97,37 $ (7 Mart&#8217;ta alt\u0131 ayl\u0131k zirve)<br \/> <strong>Nisan 2025<\/strong>: 85-90 aral\u0131\u011f\u0131 (konsolidasyon d\u00f6nemi)<br \/> <strong>May\u0131s 2025<\/strong>: 73,31 $ (15 May\u0131s&#8217;ta alt\u0131 ayl\u0131k dip &#8211; tarife endi\u015feleri)<br \/> <strong>Haziran 2025<\/strong>: 79,16 $ (toparlanma ba\u015flad\u0131)<br \/> <strong>Temmuz 2025<\/strong>: 78,12 $ (yaz d\u00f6nemi istikrar\u0131)<br \/> <strong>A\u011fustos 2025<\/strong>: 84,21 $ (mevcut toparlanma ivmesi)<\/p>\n<p>Bu, May\u0131s diplerinden itibaren <strong>%14,87&#8217;lik bir toparlanma<\/strong> anlam\u0131na geliyor ve hissenin gerilemelerden toparlanma yetene\u011fini g\u00f6steriyor (<a href=\"https:\/\/www.barchart.com\/stocks\/quotes\/mrk\/performance\">Performans Verileri<\/a>). Zirve ve dipler aras\u0131ndaki yakla\u015f\u0131k 24 $&#8217;l\u0131k i\u015flem aral\u0131\u011f\u0131, ila\u00e7 hisselerinde zamanlaman\u0131n neden \u00f6nemli oldu\u011funu a\u00e7\u0131kl\u0131yor.<\/p>\n<h3>Volatilitenin Sebebi Nedir?<\/h3>\n<ul>\n<li><strong>May\u0131s&#8217;taki tarife endi\u015feleri<\/strong> keskin d\u00fc\u015f\u00fc\u015fe neden oldu<\/li>\n<li><strong>Keytruda patent u\u00e7urumu<\/strong> kayg\u0131s\u0131 sat\u0131\u015f bask\u0131s\u0131 yaratt\u0131<\/li>\n<li><strong>Temmuz&#8217;daki g\u00fc\u00e7l\u00fc 2. \u00e7eyrek kazan\u00e7lar\u0131<\/strong> destek sa\u011flad\u0131<\/li>\n<li><strong>2025 boyunca yeni ila\u00e7 onaylar\u0131<\/strong> g\u00fcven olu\u015fturdu<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 Beklentileri<\/h2>\n<h3>2025 Y\u0131l Sonu: 85-95 $ Aral\u0131\u011f\u0131 \u2192 AL<\/h3>\n<p>Analistler, Merck&#8217;in 2025&#8217;i 85-95 $ aras\u0131nda tamamlayabilece\u011fini \u00f6ng\u00f6r\u00fcyor; bu da mevcut seviyelerden %1-13 aras\u0131nda potansiyel y\u00fckseli\u015f anlam\u0131na geliyor. 77,08 $&#8217;l\u0131k muhafazakar tahmin, son momentum g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda fazla k\u00f6t\u00fcmser g\u00f6r\u00fcn\u00fcyor (<a href=\"https:\/\/tradersunion.com\/currencies\/forecast\/mrk-usd\/\">2025 Tahmini<\/a>).<\/p>\n<h3>2026 Projeksiyonu: 89-92 $<\/h3>\n<p>Y\u0131l ortas\u0131 hedefleri yakla\u015f\u0131k 89,63 $ ve y\u0131l sonu 92,35 $ seviyeleri, \u00fcr\u00fcn hatt\u0131 geli\u015fmeleri ve pazar geni\u015flemesine dayanarak makul g\u00f6r\u00fcn\u00fcyor.<\/p>\n<h3>2028 Beklentisi: 101-104 $<\/h3>\n<p>2028&#8217;e kadar Merck&#8217;in \u00e7e\u015fitlendirme \u00e7abalar\u0131 meyvesini vermeli ve hisse senedi y\u0131llard\u0131r ilk kez 100 $&#8217;\u0131n \u00fczerine \u00e7\u0131kmal\u0131.<\/p>\n<h3>2030 Vizyonu: 117-187 $<\/h3>\n<p>Uzun vadeli tahminler, patent biti\u015fleri ve yeni ila\u00e7 ba\u015far\u0131s\u0131na ili\u015fkin belirsizli\u011fi yans\u0131tarak muhafazakar 117 $ ile iyimser 187 $ aras\u0131nda geni\u015f bir aral\u0131kta de\u011fi\u015fiyor (<a href=\"https:\/\/stockscan.io\/stocks\/MRK\/forecast\">Uzun Vadeli Projeksiyonlar<\/a>).<\/p>\n<p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut de\u011ferleme, 9 kat ileriye d\u00f6n\u00fck F\/K oran\u0131yla tarihsel ortalamalara g\u00f6re \u00f6nemli bir indirim sunuyor.<\/p>\n<h2>\u26a0\ufe0f \u00d6nemli Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Patent U\u00e7urumu Kayg\u0131s\u0131<\/strong>: Keytruda&#8217;n\u0131n yakla\u015fan patent s\u00fcresi belirsizlik yarat\u0131yor, \u00f6nlemlere ra\u011fmen (<a href=\"https:\/\/monexa.ai\/blog\/merck-s-strategy-navigating-keytruda-cliff-with-pi-MRK-2025-06-05\">Patent Stratejisi<\/a>)<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA onay s\u00fcre\u00e7leri zorlu ve \u00f6ng\u00f6r\u00fclemez olmaya devam ediyor<\/li>\n<li><strong>Tarife Maruziyeti<\/strong>: 2025 i\u00e7in beklenen 200 milyon $ tarife maliyeti k\u00e2r marjlar\u0131n\u0131 etkileyebilir<\/li>\n<li><strong>Rekabetin Artmas\u0131<\/strong>: Rakipler benzer onkoloji tedavileri geli\u015ftiriyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 G\u00fcc\u00fc<\/strong>: Geli\u015ftirilmekte olan 20 potansiyel blockbuster ila\u00e7, 50 milyar $&#8217;dan fazla f\u0131rsat sunuyor<\/li>\n<li><strong>Son FDA Ba\u015far\u0131lar\u0131<\/strong>: KEYTRUDA geni\u015flemesi, ENFLONSIA onay\u0131, WELIREG pediatrik endikasyonu<\/li>\n<li><strong>Stratejik Sat\u0131n Alma<\/strong>: Solunum portf\u00f6y\u00fcne Ohtuvayre ekleyen 10 milyar $&#8217;l\u0131k Verona Pharma anla\u015fmas\u0131<\/li>\n<li><strong>WINREVAIR Ba\u015far\u0131s\u0131<\/strong>: 2. \u00e7eyrekte 336 milyon $ sat\u0131\u015f, toplamda 1 milyar $&#8217;\u0131 a\u015fan gelir<\/li>\n<li><strong>Temett\u00fc G\u00fcc\u00fc<\/strong>: %3,8 getiri ve s\u00fcrd\u00fcr\u00fclebilir %49 \u00f6deme oran\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Haftal\u0131k veya ayl\u0131k al\u0131mlarla dolar maliyeti ortalamas\u0131 yap\u0131n<\/li>\n<li><strong>Kazan\u00e7 uyar\u0131lar\u0131 kurun<\/strong> &#8211; Potansiyel giri\u015f noktalar\u0131 i\u00e7in 30 Ekim civar\u0131n\u0131 takip edin<\/li>\n<li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong> &#8211; \u0130la\u00e7 hisseleri, \u00fcr\u00fcn hatt\u0131n\u0131n olgunla\u015fmas\u0131 i\u00e7in sab\u0131r gerektirir<\/li>\n<li><strong>Do\u011fru \u00e7e\u015fitlendirin<\/strong> &#8211; MRK&#8217;yi toplam portf\u00f6y\u00fcn %5-10&#8217;u ile s\u0131n\u0131rlay\u0131n<\/li>\n<\/ol>\n<p>Espiri: &#8220;MRK ticareti yapmak, klinik deneme sonu\u00e7lar\u0131n\u0131 beklemek gibidir &#8211; bazen \u00e7\u0131\u011f\u0131r a\u00e7an tedavi onay\u0131 al\u0131rs\u0131n\u0131z, bazen yan etkilerle kar\u015f\u0131la\u015f\u0131rs\u0131n\u0131z. Her hal\u00fckarda, g\u00fc\u00e7l\u00fc mide ilac\u0131na ihtiyac\u0131n\u0131z olacak!&#8221;<\/p>\n<h2>\u2705 Merck &#038; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NYSE eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;MRK&#8221; sembol\u00fcn\u00fc aray\u0131n<\/td>\n<td>Sadece &#8220;Merck&#8221; de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilite s\u0131ras\u0131nda fazla \u00f6deme yapman\u0131z\u0131 engeller<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>G\u00f6zden ge\u00e7irin ve onaylay\u0131n<\/td>\n<td>Son onaydan \u00f6nce komisyon oranlar\u0131n\u0131 kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, borsaya giri\u015fin daha az korkutucu olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in ideal<\/li>\n<li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> &#8211; Herhangi bir resmi kimlik y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Kripto, e-c\u00fczdan ve geleneksel bankac\u0131l\u0131k ile esneklik<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong> &#8211; MRK gibi pahal\u0131 hisselerin k\u00fc\u00e7\u00fck par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, sa\u011fl\u0131k sekt\u00f6r\u00fc b\u00fcy\u00fcmesine maruz kalmak isteyen yeni ba\u015flayanlar i\u00e7in karma\u015f\u0131k ila\u00e7 hisselerini \u00e7ok daha kolay hale getiriyor.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Merck: Sa\u011fl\u0131kta Yenilik Motoru<\/h2>\n<p>Merck, y\u0131ll\u0131k yakla\u015f\u0131k 61 milyar $ gelir ve 330 milyar $&#8217;\u0131n \u00fczerinde piyasa de\u011feri ile bir ila\u00e7 devi olarak duruyor (<a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/mrk-history-mission-ownership\">\u015eirket Metrikleri<\/a>). \u00dcnl\u00fc kanser ila\u00e7lar\u0131n\u0131n \u00f6tesinde, a\u015f\u0131 geli\u015ftirme, hayvan sa\u011fl\u0131\u011f\u0131 ve \u00e7e\u015fitli terap\u00f6tik alanlarda lider konumda.<\/p>\n<p>\u015eirketin \u00fcr\u00fcn hatt\u0131 2021&#8217;den bu yana neredeyse \u00fc\u00e7 kat\u0131na \u00e7\u0131kt\u0131; 20 potansiyel blockbuster ila\u00e7, gelecekte 50 milyar $&#8217;dan fazla gelir potansiyeli sunuyor (<a href=\"https:\/\/fortune.com\/well\/2025\/02\/04\/merck-touts-new-blockbuster-drugs-50-billion-potential\/\">\u00dcr\u00fcn Hatt\u0131 De\u011feri<\/a>). Son ba\u015far\u0131lar aras\u0131nda WINREVAIR&#8217;in 2. \u00e7eyrekte 336 milyon $ sat\u0131\u015f yapmas\u0131 ve solunum ilac\u0131 Ohtuvayre&#8217;yi ekleyen 10 milyar $&#8217;l\u0131k Verona Pharma sat\u0131n almas\u0131 yer al\u0131yor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: Merck, 1898&#8217;de ABD&#8217;de ticari olarak kullan\u0131lan ilk \u00e7i\u00e7ek hastal\u0131\u011f\u0131 a\u015f\u0131s\u0131n\u0131 satt\u0131 ve bug\u00fcn hala bebeklerde RSV \u00f6nlemi i\u00e7in FDA onay\u0131 alan ENFLONSIA ile a\u015f\u0131 tarihinde yer almaya devam ediyor!<\/p>\n"},"faq":[{"question":"Merck hisseleri nereden al\u0131nabilir?","answer":"Merck hisseleri NYSE gibi b\u00fcy\u00fck borsalarda i\u015flem g\u00f6r\u00fcr. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden MRK sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Merck hisseleri i\u00e7in en kritik tarih nedir?","answer":"30 Ekim 2025, Merck'in 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 tarih olarak kritik \u00f6neme sahiptir ve hisse fiyat\u0131nda \u00f6nemli hareketler yaratabilir."},{"question":"Merck hisselerinin volatilitesinin ba\u015fl\u0131ca nedenleri nelerdir?","answer":"Tarife endi\u015feleri, Keytruda patent s\u00fcresi kayg\u0131s\u0131, g\u00fc\u00e7l\u00fc kazan\u00e7 raporlar\u0131 ve yeni ila\u00e7 onaylar\u0131 volatiliteyi etkileyen ba\u015fl\u0131ca fakt\u00f6rlerdir."},{"question":"Merck hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"2025-2030 aras\u0131nda fiyatlar\u0131n 85 $ ile 187 $ aras\u0131nda de\u011fi\u015fmesi bekleniyor; uzun vadede g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme ve \u00e7e\u015fitlendirme potansiyeli bulunuyor."},{"question":"Yeni ba\u015flayanlar Merck hissesi al\u0131rken nelere dikkat etmeli?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131p dolar maliyeti ortalamas\u0131 yapmal\u0131, kazan\u00e7 raporlar\u0131n\u0131 takip etmeli, uzun vadeli d\u00fc\u015f\u00fcnmeli ve portf\u00f6yde MRK hisselerini %5-10 aras\u0131nda tutmal\u0131d\u0131rlar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Merck hisseleri nereden al\u0131nabilir?","answer":"Merck hisseleri NYSE gibi b\u00fcy\u00fck borsalarda i\u015flem g\u00f6r\u00fcr. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden MRK sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Merck hisseleri i\u00e7in en kritik tarih nedir?","answer":"30 Ekim 2025, Merck'in 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 tarih olarak kritik \u00f6neme sahiptir ve hisse fiyat\u0131nda \u00f6nemli hareketler yaratabilir."},{"question":"Merck hisselerinin volatilitesinin ba\u015fl\u0131ca nedenleri nelerdir?","answer":"Tarife endi\u015feleri, Keytruda patent s\u00fcresi kayg\u0131s\u0131, g\u00fc\u00e7l\u00fc kazan\u00e7 raporlar\u0131 ve yeni ila\u00e7 onaylar\u0131 volatiliteyi etkileyen ba\u015fl\u0131ca fakt\u00f6rlerdir."},{"question":"Merck hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"2025-2030 aras\u0131nda fiyatlar\u0131n 85 $ ile 187 $ aras\u0131nda de\u011fi\u015fmesi bekleniyor; uzun vadede g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme ve \u00e7e\u015fitlendirme potansiyeli bulunuyor."},{"question":"Yeni ba\u015flayanlar Merck hissesi al\u0131rken nelere dikkat etmeli?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131p dolar maliyeti ortalamas\u0131 yapmal\u0131, kazan\u00e7 raporlar\u0131n\u0131 takip etmeli, uzun vadeli d\u00fc\u015f\u00fcnmeli ve portf\u00f6yde MRK hisselerini %5-10 aras\u0131nda tutmal\u0131d\u0131rlar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck &amp; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck &amp; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck &amp; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T13:12:04+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Merck &#038; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Merck &#038; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m\",\"datePublished\":\"2025-08-19T13:12:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\",\"name\":\"Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck & Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-08-19T13:12:04+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &#038; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Merck &#038; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck & Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/","og_locale":"tr_TR","og_type":"article","og_title":"Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck & Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T13:12:04+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Merck &#038; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Merck &#038; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m","datePublished":"2025-08-19T13:12:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/","name":"Merck & Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Merck & Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-08-19T13:12:04+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-merck\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Merck &#038; Co., Inc. (MRK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Merck &#038; Co., Inc. (MRK) Hisse Senedine Yat\u0131r\u0131m"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":337935,"slug":"how-to-buy-merck","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Merck & Co., Inc. (MRK) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Merck & Co., Inc. (MRK)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-merck\/"},"pt_AA":{"locale":"pt_AA","id":337936,"slug":"how-to-buy-merck","post_title":"Como comprar a\u00e7\u00f5es da Merck & Co., Inc. (MRK) - Investimento em a\u00e7\u00f5es da Merck & Co., Inc. (MRK)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-merck\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/337932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=337932"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/337932\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=337932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=337932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=337932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}